Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 35

Sort by

Sort Order Select

Journal Articles

Excellent long-term outcomes after alemtuzumab-based hematopoietic cell transplantation (HCT) for severe aplastic anemia (SAA) and inherited bone marrow failure syndromes (IBMF): A 25-year British society of blood and marrow transplantation and cellular therapy (BSBMTCT) retrospective analysis of 1754 patients from the United Kingdom (UK)

Austin Kulasekararaj, Kanchan Rao, Rachel Pearce, Julia Lee, Marie Wilson, Anjum Khan, Rachel Protheroe, Pramila Krishnamurthy, R.F. Wynn, Persis Amrolia, Victoria Potter

Blood (2025) 146 (Supplement 1): 984.

https://doi.org/10.1182/blood-2025-984

Published: 2025

Journal Articles

Improved outcomes following allogeneic hematopoietic stem cell transplantation in patients with DDX41-mutated myeloid neoplasms: A prospective analysis of survival, GVHD, and transplant-related mortality

Shreyas Hanmantgad, Alan Mitchell, Kayleigh Mccloskey, James Aries, Francesco Versino, Roochi Trikha, Shreyans Gandhi, Madson Correia De Farias, Maria Cuadrado, Mili Shah, Varun Mehra, Pramila Krishnamurthy, Michelle Kenyon, Victoria Potter, Austin Kulasekararaj

Blood (2025) 146 (Supplement 1): 6083.

https://doi.org/10.1182/blood-2025-6083

Published: 2025

Journal Articles

17p loss in TP53-non-mutated myeloid neoplasms confers survival comparable to TP53-mutated disease

Blood (2025) 146 (Supplement 1): 3858.

https://doi.org/10.1182/blood-2025-3858

Published: 2025

Journal Articles

DDX41-related myeloid neoplasms: Insights and treatment landscape in 250 patients managed at a large tertiary centre

Francesco Versino, Shreyas Hanmantgad, Pramila Krishnamurthy, Victoria Potter, Roochi Trikha, Mili Shah, Varun Mehra, Lynn Quek, Guy Hannah, Henry Wood, Shreyans Gandhi, Joanna Large, Clair Engelbrecht, Katie Snape, Guilherme Sapinho, Steve Best, Kar Lok Kong, Austin Kulasekararaj

Blood (2025) 146 (Supplement 1): 5262.

https://doi.org/10.1182/blood-2025-5262

Published: 2025

Journal Articles

Detection of KMT2A fusion transcripts after induction chemotherapy is strongly predictive of outcome in KMT2A rearranged AML: Results of an international collaborative study

Blood (2025) 146 (Supplement 1): 346.

https://doi.org/10.1182/blood-2025-346

Published: 2025

Journal Articles

Role of Cidofovir in the Treatment of BK Virus Haemorrhagic Cystitis in Patients Undergoing T- Cell Deplete Stem Cell Transplant and Cellular Therapies

Shreyas Hanmantgad, Samitha Fernando, Mark Zuckerman, Pamella Paul, Yahya Almohmeed, Mili Shah, Pramila Krishnamurthy, Daniele Avenoso, Antonio Pagliuca, Austin G. Kulasekararaj, Victoria Potter, Varun Mehra

Blood (2024) 144 (Supplement 1): 7293.

https://doi.org/10.1182/blood-2024-208440

Published: 2024

Journal Articles

Prospective Cohort Study of Non-COVID Infection in Patients with AML/MDS Undergoing Treatment: Implications for Practice

Blood (2024) 144 (Supplement 1): 120.

https://doi.org/10.1182/blood-2024-200732

Published: 2024

Journal Articles

Clonal Haematopoiesis with TP53 Mutations Exhibits Abnormal Erythropoiesis and Erythroid Metabolic Stress

Blood (2024) 144 (Supplement 1): 944.

https://doi.org/10.1182/blood-2024-200108

Published: 2024

Journal Articles

A Dedicated System Accounting for Specific Germline/Somatic Genomic Constellations Is Essential to Predict Outcomes in DDX41 -Mutant Myeloid Neoplasia

Blood (2024) 144 (Supplement 1): 1332.

https://doi.org/10.1182/blood-2024-194024

Published: 2024

Journal Articles

Real-World Treatment Patterns and Outcomes with Oral Azacitidine Maintenance Therapy in Patients with Acute Myeloid Leukemia

Pramila Krishnamurthy, Katherine Houghton, Nicola Lorenz, Paula Williams, Lisa Currie, Carlos E. Vigil, Nomthandazo Ziba, Fareedat Bello, Jan Sieluk, Maria Strocchia, Yeran Li, Silke Kapp-Schwoerer

Blood (2024) 144 (Supplement 1): 2425.

https://doi.org/10.1182/blood-2024-198362

Published: 2024

Journal Articles

Molecular MRD is strongly prognostic in patients with NPM1 -mutated AML receiving venetoclax-based nonintensive therapy

Blood (2024) 143 (4): 336–341.

https://doi.org/10.1182/blood.2023021579

Published: 2024

Includes: Supplemental data

Journal Articles

Impact of Somatic Second Hit and Comutations in Myeloid Neoplasms with Germline DDX41 Mutations

Guilherme Mendes Sapinho, Pramila Krishnamurthy, Guy Hannah, Shreyans Gandhi, Victoria Potter, Mili Shah, Nicholas Lea, Clair Engelbrecht, Heidre Bezuidenhout, Katie Snape, Steve Best, Austin Kulasekararaj

Blood (2023) 142 (Supplement 1): 6446.

https://doi.org/10.1182/blood-2023-189451

Published: 2023

Journal Articles

Real-World Mobilization, Harvest, and Transplant Outcomes in Newly Diagnosed Multiple Myeloma Patients Receiving D-VTd: A UK Centre Experience

Blood (2023) 142 (Supplement 1): 4971.

https://doi.org/10.1182/blood-2023-177624

Published: 2023

Journal Articles

Outcome Prediction in DDX41 -Mutant Myelodysplastic Syndromes Is Not Possible with General Disease Schemes and Requires a Dedicated Risk Scoring System

Carmelo Gurnari, Hideki Makishima, Arda Durmaz, Ryunosuke Saiki, Guilherme Mendes Sapinho, Alex Bataller, Lukasz P. Gondek, Yasuhito Nannya, Steve Best, Pramila Krishnamurthy, Hussein Awada, Enrico Attardi, Valeria Visconte, Maria Teresa Voso, Amy E. DeZern, Guillermo Garcia-Manero, Austin Kulasekararaj, Jaroslaw P. Maciejewski, Seishi Ogawa

Blood (2023) 142 (Supplement 1): 316.

https://doi.org/10.1182/blood-2023-178116

Published: 2023

Journal Articles

Double, double, TP53, and trouble in myelofibrosis

Pramila Krishnamurthy

Blood (2023) 141 (23): 2793–2795.

https://doi.org/10.1182/blood.2023020421

Published: 2023

Journal Articles

Germ line DDX41 mutations define a unique subtype of myeloid neoplasms

Hideki Makishima, Ryunosuke Saiki, Yasuhito Nannya, Sophia Korotev, Carmelo Gurnari, June Takeda, Yukihide Momozawa, Steve Best, Pramila Krishnamurthy, Tetsuichi Yoshizato, Yoshiko Atsuta, Yusuke Shiozawa, Yuka Iijima-Yamashita, Kenichi Yoshida, Yuichi Shiraishi, Yasunobu Nagata, Nobuyuki Kakiuchi, Makoto Onizuka, Kenichi Chiba, Hiroko Tanaka, Ayana Kon, Yotaro Ochi, Masahiro M. Nakagawa, Rurika Okuda, Takuto Mori, Akinori Yoda, Hidehiro Itonaga, Yasushi Miyazaki, Masashi Sanada, Takayuki Ishikawa, Shigeru Chiba, Hisashi Tsurumi, Senji Kasahara, Carsten Müller-Tidow, Akifumi Takaori-Kondo, Kazuma Ohyashiki, Toru Kiguchi, Fumihiko Matsuda, Joop H. Jansen, Chantana Polprasert, Piers Blombery, Yoichiro Kamatani, Satoru Miyano, Luca Malcovati, Torsten Haferlach, Michiaki Kubo, Mario Cazzola, Austin G. Kulasekararaj, Lucy A. Godley, Jaroslaw P. Maciejewski, Seishi Ogawa

Blood (2023) 141 (5): 534–549.

https://doi.org/10.1182/blood.2022018221

Published: 2023

Includes: Supplemental data

Journal Articles

Molecular MRD Assessment Is Strongly Prognostic in Patients with NPM1 Mutated AML Receiving Venetoclax Based Non-Intensive Therapy

Blood (2022) 140 (Supplement 1): 2033–2035.

https://doi.org/10.1182/blood-2022-159467

Published: 2022

Journal Articles

High Molecular Response Rate and Overall Survival with FLT3 Inhibitors As MRD-Guided Salvage Treatment for Molecular Failure in AML

Blood (2022) 140 (Supplement 1): 2002–2004.

https://doi.org/10.1182/blood-2022-159503

Published: 2022

Journal Articles

Venetoclax-Based Non-Intensive Combinations Successfully Salvage Molecular Relapse of Acute Myeloid Leukemia and Are an Important Bridge to Cellular Therapy in Relapsed/Refractory Disease - Real-World Data from a UK-Wide Programme

Blood (2022) 140 (Supplement 1): 9016–9018.

https://doi.org/10.1182/blood-2022-167097

Published: 2022

Journal Articles

Germline Risks and Clinical Impacts of DDX41 Mutations in Myeloid Malignancies

Hideki Makishima, Ryunosuke Saiki, Yasuhito Nannya, Sophia C. Korotev, Carmelo Gurnari, June Takeda, Yukihide Momozawa, Steve Best, Pramila Krishnamurthy, Tetsuichi Yoshizato, Yoshiko Atsuta, Yusuke Shiozawa, Yuka Iijima-Yamashita, Kenichi Yoshida, Yuichi Shiraishi, Yasunobu Nagata, Nobuyuki Kakiuchi, Makoto Onizuka, Kenichi Chiba, Hiroko Tanaka, Ayana Kon, Yotaro Ochi, Masahiro Marshall Nakagawa, Rurika Okuda, Takuto Mori, Akinori Yoda, Hidehiro Itonaga, Yasushi Miyazaki, Masashi Sanada, Takayuki Ishikawa, Shigeru Chiba, Hisashi Tsurumi, Senji Kasahara, Carsten Müller-Tidow, Akifumi Takaori-Kondo, Kazuma Ohyashiki, Toru Kiguchi, Fumihiko Matsuda, Joop H. Jansen, Chantana Polprasert, Piers Blombery, Yoichiro Kamatani, Satoru Miyano, Luca Malcovati, Torsten Haferlach, Michiaki Kubo, Mario Cazzola, Austin Kulasekararaj, Lucy A. Godley, Jaroslaw P. Maciejewski, Seishi Ogawa

Blood (2022) 140 (Supplement 1): 208–210.

https://doi.org/10.1182/blood-2022-158851

Published: 2022

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Improved outcomes following allogeneic hematopoietic stem cell transplantation in patients with DDX41-mutated myeloid neoplasms: A prospective analysis of survival, GVHD, and transplant-related mortality

17p loss in TP53-non-mutated myeloid neoplasms confers survival comparable to TP53-mutated disease

DDX41-related myeloid neoplasms: Insights and treatment landscape in 250 patients managed at a large tertiary centre

Detection of KMT2A fusion transcripts after induction chemotherapy is strongly predictive of outcome in KMT2A rearranged AML: Results of an international collaborative study

Role of Cidofovir in the Treatment of BK Virus Haemorrhagic Cystitis in Patients Undergoing T- Cell Deplete Stem Cell Transplant and Cellular Therapies

Prospective Cohort Study of Non-COVID Infection in Patients with AML/MDS Undergoing Treatment: Implications for Practice

Clonal Haematopoiesis with TP53 Mutations Exhibits Abnormal Erythropoiesis and Erythroid Metabolic Stress

A Dedicated System Accounting for Specific Germline/Somatic Genomic Constellations Is Essential to Predict Outcomes in DDX41 -Mutant Myeloid Neoplasia

Real-World Treatment Patterns and Outcomes with Oral Azacitidine Maintenance Therapy in Patients with Acute Myeloid Leukemia

Molecular MRD is strongly prognostic in patients with NPM1 -mutated AML receiving venetoclax-based nonintensive therapy

Impact of Somatic Second Hit and Comutations in Myeloid Neoplasms with Germline DDX41 Mutations

Real-World Mobilization, Harvest, and Transplant Outcomes in Newly Diagnosed Multiple Myeloma Patients Receiving D-VTd: A UK Centre Experience

Outcome Prediction in DDX41 -Mutant Myelodysplastic Syndromes Is Not Possible with General Disease Schemes and Requires a Dedicated Risk Scoring System

Double, double, TP53, and trouble in myelofibrosis

Germ line DDX41 mutations define a unique subtype of myeloid neoplasms

Molecular MRD Assessment Is Strongly Prognostic in Patients with NPM1 Mutated AML Receiving Venetoclax Based Non-Intensive Therapy

High Molecular Response Rate and Overall Survival with FLT3 Inhibitors As MRD-Guided Salvage Treatment for Molecular Failure in AML

Venetoclax-Based Non-Intensive Combinations Successfully Salvage Molecular Relapse of Acute Myeloid Leukemia and Are an Important Bridge to Cellular Therapy in Relapsed/Refractory Disease - Real-World Data from a UK-Wide Programme

Germline Risks and Clinical Impacts of DDX41 Mutations in Myeloid Malignancies

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only